Background: A specific psychotherapy for chronic depression, the Cognitive Behavioral Analysis System of Psychotherapy (CBASP), was compared to escitalopram (ESC). Methods: Sixty patients with chronic major depression were randomized to ‘CBASP' (22 sessions) or ‘ESC plus clinical management' (ESC/CM) at two treatment sites. The primary outcome measure was the score on the Montgomery-Asberg Depression Rating Scale (MADRS) after 8 weeks of acute treatment assessed by blinded raters. In the case of nonimprovement (<20% reduction in the MADRS score), the other condition was augmented for the following 20 weeks of extended treatment. Secondary end points were, among others, depressive symptoms, remission (MADRS score of ≤9) and response rates (reduction of MADRS score of ≥50%) 28 weeks after randomization. Results: An intent-to-treat analysis revealed that clinician-rated depression scores decreased significantly after 8 and 28 weeks with no significant differences between the groups. The response rates after 28 weeks of treatment were high (CBASP: 68.4%, ESC/CM: 60.0%), and the remission rates were moderate (CBASP: 36.8%, ESC/CM: 50.0%) with neither group being superior. Nonimprovers to the initial treatment caught up with the initial improvers in terms of depression scores and response and remission rates by the end of the treatment after being augmented with the respective other condition. Conclusions: CBASP and ESC/CM appear to be equally effective treatment options for chronically depressed outpatients. For nonimprovers to the initial treatment, it is efficacious to augment with medication in the case of nonresponse to CBASP and vice versa.

Keywords:
Chronic depression, Randomized controlled trial, Psychotherapy, Cognitive behavioral analysis system of psychotherapy, Escitalopram
1.
Angst J, Gamma A, Rossler W, Ajdacic V, Klein DN: Long-term depression versus episodic major depression: results from the prospective Zurich study of a community sample. J Affect Disord 2009;115:112-121.
2.
Agosti V: Predictors of remission from chronic depression: a prospective study in a nationally representative sample. Compr Psychiatry 2014;55:463-467.
3.
Klein DN: Classification of depressive disorders in the DSM-V: proposal for a two-dimension system. J Abnorm Psychol 2008;117:552-560.
4.
Murphy JA, Byrne GJ: Prevalence and correlates of the proposed DSM-5 diagnosis of chronic depressive disorder. J Affect Disord 2012;139:172-180.
5.
Satyanarayana S, Enns MW, Cox BJ, Sareen J: Prevalence and correlates of chronic depression in the Canadian community health survey: mental health and well-being. Can J Psychiatry 2009;54:389-398.
6.
Kocsis JH, Gelenberg AJ, Rothbaum B, Klein DN, Trivedi MH, Manber R, Keller MB, Howland R, Thase ME: Chronic forms of major depression are still undertreated in the 21st century: systematic assessment of 801 patients presenting for treatment. J Affect Disord 2008;110:55-61.
7.
Spijker J, van Straten A, Bockting CL, Meeuwissen JA, van Balkom AJ: Psychotherapy, antidepressants, and their combination for chronic major depressive disorder: a systematic review. Can J Psychiatry 2013;58:386-392.
8.
Craighead WE, Dunlop BW: Combination psychotherapy and antidepressant medication treatment for depression: for whom, when, and how. Annu Rev Psychol 2014;65:267-300.
9.
Kriston L, vonWolff A, Westphal A, Hölzel LP, Härter M: Efficacy and acceptability of acute treatments for persistent depressive disorder: a network meta-analysis. Depress Anxiety 2014;8:621-630.
10.
Klein DN, Shankman SA, Rose S: Ten-year prospective follow-up study of the naturalistic course of dysthymic disorder and double depression. Am J Psychiatry 2006;163:872-880.
11.
Sung SC, Haley CL, Wisniewski SR, Fava M, Nierenberg AA, Warden D, Morris DW, Kurian BT, Trivedi MH, Rush AJ; CO-MED Study Team: The impact of chronic depression on acute and long-term outcomes in a randomized trial comparing selective serotonin reuptake inhibitor monotherapy versus each of 2 different antidepressant medication combinations. J Clin Psychiatry 2012;73:967-976.
12.
Keller MB, Gelenberg AJ, Hirschfeld RM, Rush AJ, Thase ME, Kocsis JH, Markowitz JC, Fawcett JA, Koran LM, Klein DN, Russell JM, Kornstein SG, McCullough JP, Davis SM, Harrison WM: The treatment of chronic depression. 2. A double-blind, randomized trial of sertraline and imipramine. J Clin Psychiatry 1998;59:598-607.
13.
Cuijpers P, van Straten A, Hollon SD, Andersson G: The contribution of active medication to combined treatments of psychotherapy and pharmacotherapy for adult depression: a meta-analysis. Acta Psychiatr Scand 2010;121:415-423.
14.
Cuijpers P, van Straten A, Schuurmans J, van Oppen P, Hollon SD, Andersson G: Psychotherapy for chronic major depression and dysthymia: a meta-analysis. Clin Psychol Rev 2010;30:51-62.
15.
McCullough JP: Treatment for Chronic Depression. Cognitive Behavioral Analysis System of Psychotherapy. New York, Guilford Press, 2000.
16.
Hollon SD, DeRubeis RJ, Fawcett J, Amsterdam JD, Shelton RC, Zajecka J, Young PR, Gallop R: Effect of cognitive therapy with antidepressant medications vs antidepressants alone on the rate of recovery in major depressive disorder: a randomized clinical trial. JAMA Psychiatry 2014;71:1157-1164.
17.
Beck AT, Rush AJ, Shaw BF, Emery G: Cognitive Therapy of Depression. NewYork, Guilford Press, 1979.
18.
Keller MB, McCullough JP, Klein DN, Arnow B, Dunner DL, Gelenberg AJ, Markowitz JC, Nemeroff CB, Russell JM, Thase ME, Trivedi MH, Zajecka J: A comparison of nefazodone, the cognitive behavioral-analysis system of psychotherapy, and their combination for the treatment of chronic depression. N Engl J Med 2000;342:1462-1470.
19.
Nemeroff CB, Heim CM, Thase ME, Klein DN, Rush AJ, Schatzberg AF, Ninan PT, McCullough JP, Weiss PM, Dunner DL, Rothbaum BO, Kornstein S, Keitner G, Keller MB: Differential responses to psychotherapy versus pharmacotherapy in patients with chronic forms of major depression and childhood trauma. Proc Natl Acad Sci U S A 2003;100:14293-14296.
20.
Kocsis JH, Gelenberg AJ, Rothbaum BO, Klein DN, Trivedi MH, Manber R, Keller MB, Leon AC, Wisniewski SR, Arnow BA, Markowitz JC, Thase ME; REVAMP Investigators: Cognitive behavioral analysis system of psychotherapy and brief supportive psychotherapy for augmentation of antidepressant nonresponse in chronic depression: the REVAMP trial. Arch Gen Psychiatry 2009;66:1178-1188.
21.
Wiersma JE, Van Schaik DJ, Hoogendorn AW, Dekker JJ, Van HL, Schoevers RA, Blom MB, Maas K, Smit JH, McCullough JP, Jr, Beekman AT, Van Oppen P: The effectiveness of the cognitive behavioral analysis system of psychotherapy for chronic depression: a randomized controlled trial. Psychother Psychosom 2014;83:263-269.
22.
Brakemeier EL, Radtke M, Engel V, Zimmermann J, Tuschen-Caffier B, Schramm E, Hautzinger M, Berger M, Normann C: Overcoming treatment-resistance in chronic depression: outcome and feasibility of the Cognitive Behavioral Analysis System of Psychotherapy as an inpatient treatment program. Psychother Psychosom 2015;84:51-56.
23.
Renner F, Cuijpers P, Huibers MJ: The effect of psychotherapy for depression on improvements in social functioning: a meta-analysis. Psychol Med 2014;44:2913-2926.
24.
Montgomery SA, Asberg M: A new depression scale designed to be sensitive to change. Br J Psychiatry 1979;134:382-389.
25.
Arnow BA, Blasey C, Manber R, Constantino MJ, Markowitz JC, Klein DN, Thase ME, Kocsis JH, Rush AJ: Dropouts versus completers among chronically depressed outpatients. J Affect Disord 2007;97:197-202.
26.
Szegedi A, Muller MJ, Anghelescu I, Klawe C, Kohnen R, Benkert O: Early improvement under mirtazapine and paroxetine predicts later stable response and remission with high sensitivity in patients with major depression. J Clin Psychiatry 2003;64:413-420.
27.
Schramm E, Schweiger U, Hohagen F, Berger M: Psychotherapie für chronische Depression [Cognitive Behavioral Analysis System of Psychotherapy (CBASP) by McCullough JP, German transl and adapt]. Munich, Elsevier, 2006.
28.
Cipriani A, Santilli C, Furukawa TA, Signoretti A, Nakagawa A, McGuire H, Churchill R, Barbui C: Escitalopram versus other antidepressive agents for depression. Cochrane Database Syst Rev 2009;2:CD006532.
29.
First M, Spitzer RL, Gibbon M, and Williams JBW: Structured Clinical Interview for DSM-IV-TR Axis I Disorders, Research Version, Clinical Trials Version (SCID-CT). New York, Biometrics Research, New York State Psychiatric Institute, 2002.
30.
First M, Gibbon M, Spitzer RL, Williams JBW, Benjamin LS: Structured Clinical Interview for DSM-IV Axis II Personality Disorders (SCID-II). Washington, American Psychiatric Press, 1997.
31.
Zimmerman M, Posternak MA, Chelminski I: Derivation of a definition of remission on the Montgomery-Asberg Depression Rating Scale corresponding to the definition of remission on the Hamilton Rating Scale for Depression. J Psychiatr Res 2004;38:577-582.
32.
Bernstein DP, Fink L, Handelsman L, Foote J, Lovejoy M, Wenzel K, Sapareto E, Ruggiero J: Initial reliability and validity of a new retrospective measure of child abuse and neglect. Am J Psychiatry 1994;151:1132-1136.
33.
Wingenfeld K, Spitzer C, Mensebach C, Grabe H, Hill A, Gast U, Schlosser N, Höpp H, Beblo T, Driessen M: The German version of the childhood trauma questionnaire (CTQ): preliminary psychometric properties. Psychother Psychosom Med Psychol 2010;11:442-450.
34.
Drieling T, Scharer LO, Langosch JM: The Inventory of Depressive Symptomatology: German translation and psychometric validation. Int J Methods Psychiatr Res 2007;16:230-236.
35.
Rush AJ, Gullion CM, Basco MR, Jarrett RB, Trivedi MH: The inventory of depressive symptomatology (IDS): psychometric properties. Psychol Med 1996;26:477-486.
36.
Endicott J, Spitzer RL, Fleiss JL, Cohen J: The global assessment scale. A procedure for measuring overall severity of psychiatric disturbance. Arch Gen Psychiatry 1976;33:766-771.
37.
The WHOQOL Group: Development of the World Health Organization WHOQOL-BREF quality of life assessment. Psychol Med 1998;28:551-558.
38.
The WHOQOL Group: WHOQOL User Manual, rev 3. Geneva, World Health Organisation Press, 2012.
39.
Duschek S, Schandry R, Hege B: Soziale Aktivität Selbstbeurteilungs-Skala (SASS). Diagnostik sozialer Funktionsstörungen bei depressiven Störungen. Göttingen, Beltz Test GmbH, 2003.
40.
StataCorp: Stata statistical software: Release 13.1 College Station, StataCorp LP, 2013.
41.
Schafer JL, Graham JW: Missing data: our view of the state of the art. Psychol Methods 2002;7:147-177.
42.
Rubin DB: Multiple imputation for nonresponse in surveys. New York, Wiley, 1987.
43.
Molenberghs G, Kenward MG: Missing data in clinical studies. West Sussex, John Wiley & Sons, 2007.
44.
Schafer JL: Analysis of incomplete multivariate data. New York, Chapman and Hall, 1997.
45.
Thase ME, Greenhouse JB, Frank E, Reynolds CF 3rd, Pilkonis PA, Hurley K, Grochocinski V, Kupfer DJ: Treatment of major depression with psychotherapy or psychotherapypharmacotherapy combinations. Arch Gen Psychiatry 1997;54:1009-1015.
46.
Cuijpers P, Huibers M, Ebert DD, Koole SL, Andersson G: How much psychotherapy is needed to treat depression? A metaregression analysis. J Affect Disord 2013;149:1-13.
47.
Cuijpers P, van Straten A, Schuurmans J, van Oppen P, Hollon SD, Andersson G: Psychotherapy for chronic major depression and dysthymia: a meta-analysis. Clin Psychol Rev 2010;30:51-62.
48.
Schatzberg AF, Rush AJ, Arnow BA, Banks PL, Blalock JA, Borian FE, Howland R, Klein DN, Kocsis JH, Kornstein SG, Manber R, Markowitz JC, Miller I, Ninan PT, Rothbaum BO, Thase ME, Trivedi MH, Keller MB: Chronic depression: medication (nefazodone) or psychotherapy (CBASP) is effective when the other is not. Arch Gen Psychiatry 2005;62:513-520.
49.
Koran LM, Gelenberg AJ, Kornstein SG, Howland RH, Friedman RA, DeBattista C, Klein D, Kocsis JH, Schatzberg AF, Thase ME, Rush AJ, Hirschfeld RM, LaVange LM, Keller MB: Sertraline versus imipramine to prevent relapse in chronic depression. J Affect Disord 2001;65:27-36.
50.
Schramm E, Zobel I, Dykierek P, Kech S, Brakemeier EL, Külz A, Berger M: Cognitive behavioral analysis system of psychotherapy versus interpersonal psychotherapy for early-onset chronic depression: a randomized pilot study. J Affect Disord 2011;129:109-116.
51.
McHugh RK, Whitton SW, Peckham AD, Welge JA, Otto MW: Patient preference for psychological vs pharmacologic treatment of psychiatric disorders: a meta-analytic review. J Clin Psychiatry 2013;74:595-602.
52.
Hollon SD, DeRubeis RJ, Shelton RC, Amsterdam JD, Salomon RM, O'Reardon JP, Lovett ML, Young PR, Haman KL, Freeman BB, Gallop R: Prevention of relapse following cognitive therapy vs medications in moderate to severe depression. Arch Gen Psychiatry 2005;62:417-422.
53.
Cuijpers P, Hollon SD, van Straten A, Bockting C, Berking M, Andersson G: Does cognitive behaviour therapy have an enduring effect that is superior to keeping patients on continuation pharmacotherapy? A meta-analysis. BMJ Open 2013;3:e002542.
54.
Teare MD, Dimairo M, Shephard N, Hayman A, Whitehead A, Walters SJ: Sample size requirements to estimate key design parameters from external pilot randomised controlled trials: a simulation study. Trials 2014;15:264.
55.
Kocsis JH, Frances AJ, Voss C, Mann JJ, Mason BJ, Sweeney J: Imipramine treatment for chronic depression. Arch Gen Psychiatry 1988;45:253-257.
56.
Kocsis JH, Leon AC, Markowitz JC, Manber R, Arnow B, Klein DN, Thase ME: Patient preference as a moderator of outcome for chronic forms of major depressive disorder treated with nefazodone, cognitive behavioral analysis system of psychotherapy, or their combination. J Clin Psychiatry 2009;70:354-361.
57.
Fava GA: Rational use of antidepressant drugs. Psychother Psychosom 2014;83:197-204.
58.
Fava GA, Gatti A, Belaise C, Guidi J, Offidani E: Withdrawal symptoms after selective serotonin reuptake inhibitors discontinuation: a systematic review. Psychother Psychosom 2015;84:72-81.
59.
Chouinard G, Chouinard VA: New classification of selective serotonin reuptake inhibitor withdrawal. Psychother Psychosom 2015;84:63-71.
60.
Richardson WS, Doster LM: Comorbidity and multimorbidity need to be placed in the context of a framework of risk, responsiveness, and vulnerability. J Clin Epidemiol 2014;67:244-246.
61.
Spijker J, van Straten A, Bockting CL, Meeuwissen JA, van Balkom AJ: Psychotherapy, antidepressants, and their combination for chronic major depressive disorder: a systematic review. Can J Psychiatry 2013;58:386-392.
© 2015 S. Karger AG, Basel
2015
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.